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Abstract
CellLrlar €sponses to stress ircluding DNA damage show multiple oplions involving the
mechanisms ofgrowth arrest. DNA repair and progmnrmcd cell dealh or apoptosis Failur€s in lhese
nechanisns can result in oncogenesis or accclerated senescence Much of the response is
coordinated by p5l. a nuclear phosphoprolein $iih a central role in ihe defences against Phys'cal.
chemical and pathogenic agcnts which challc ge lhe DNA integrit) lhe p53 parhwavs fo.
mobilising lhe cellular detnces are finked to the pRbih2F pathways regulating th€ cell cvcle
progrcssion This paper ainrs to revie$ the cun'enl undentanding on the nctworks and main
molecular machinery ofthese processes. In addi l ion. rhe inrpl icat ions on cel lular decision making for
the defences as well as evolutionary aspects ofthcse mechanisms are disc ssed ir briet:
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JK(;LI l  )003: l0(Edtt i  Khusuv t06'1la
DtethuAdn l t .Jaknla
lntroduction
Responses to damag€: cell cycl€
arrest, repair or apoptosis
1he importance of thc nLrclear
phosphoproreirr p53 in rhe D\A
nrarntenaoce is vident from the observatio
rhar rhc corre.p^[dirF tumor 5rrppfe\s' l
gcne is the fiosi comnrolrly altered getre i
l l | | | |ran ci lr)cer. \ \ i lh a mulal iurr l equencr in
tumors of about 5070. Many tumors wtthoul
p5J rnutations involve either other




r n c c h a r r r s | l r .  o l  p 5 I  r r r a c l i \ a l i , ' i r  o r
dl leraron. ' , r '  delect i  in the cel lular
pathr{a}s regulaleo b} p) i .  uermllne
mular ions of p5l .  as in lhe Li-Fraumenl
srndromc. arc associaled $i th an elevated
f i 'k de\elop||rg a vartelv of cancers al  an
early age. ID addit ioD, murine models
lacking funct ioDal p53 develop cancers at
car l l  age. I  nslre..cd Lcl l5 corr lain on.r
Inrnor a,nounl\  ol  p5J prutein. \  hich i \
rargered b) the prolein MDMI lor nuclear
rran\pon and ubiqui l in-medialed
lrrr(d/i t/ Srf f/,r /S ljdnu .a. ( onrn S, Rahdtdja TW Lto K Ikeda-MA
pfoleol ls is.  Stress e g. dlrc 1o DNA darnage
can slabi l ise p5i b\  scveral  nrechanisnrs thal
can ei ther rnake p5J rcsistant lo MD\4: of
inhibi i  i1.  leadrng to p5: l  accumulal ion rnd
subsequent cel lular del 'ence rcacl ion5
cdrfdinrred b) p5i.  Ihe p5l path\\a),
nrobi l ised in stresrcd ccl ls are palt ia l l )
l inkcd 1o the pRb (Rel inoblastona pn)rern)
and L2l path\ lays which rcgul.  e the cel
c\cle progressiol  also in unslressed ccl ls
\ \ ihcn acl ivated. pRb inhibi ts CrlS l ransi t ion
and lherebr ccl l  prol i feral ion b) binding thc
E:F transcr ipl ion f 'actors Al lcrat idrs of loss
of funct ion i rr  thc pRbrlr l l i  pathwa\s afc
also t icqucnl l )  obsef\ed i i r  {Uinors. e\en
! \ i l h  l i r l l \  l L r n c t r o n i l  ( \ \ i l d  l t p e ) p i l . "
K 0!\n agenls of D\A da r, tgc
ir lc lude ph\sical  st i , rul i  l ike t lV l ighr.  X-rar
and garnma irradi  t ()n.  a r l ide era\ ol_
chcmical mutagens and carciDoger,s.
i rc ludin{ chenrorhcrapcul ic agents. and
cef l la in padrogcns. e.g. l le l tahdLtet Pthrt
(ga(r ic cancef).  hunrarr papi l loma\ i fu\
( l l P \ ' .  c e n r c a l  c a n c e r ) .   r d  h c p a t i t i s  B a n d
C rrf t rscs {HB\ ' .  HC\ ' .  l l \cr  cancea).  ancl
probabl) man\ nrcre remain 1(r be
disco\efed and charactcr ised. Ihe damage
can fesult  in a part iculaf ly selere tcndenc\
to\!afds cafcinogenesis i f  the damage
e\rends 1() thc \ ' ! - r \  part  of  the genonrc
\\hich is fequifed for tnaintaining the I) \A
infegri t )  1n addi l ion lo e\tefnal agelt ts.  hosl
. I , . ( p r i l - . i  r r \  , ,  d  c o l t  b U l i n g  f d . l . , r  i r l
carcinogenesis.  and this suscept i i l i l i t !  can
be heredita| \  or acquircd. l loseVer. wirh
intacl  def 'ensive path* 'als.  DNA danrage
and olhef cel lular stress faclors such as
oncogene act ivat ioD. hrpoxia or heat si tock
rvj l l  invoke rrobi l isat ion of an ana) of
rcacl ions (Figs I  to l ) .
Whcn the damace is not loo
extensirc and does nol cf ipple thc DNA
f e p d . r  I n n . l r . I ( r \ .  t l  .  , ' r j r l r c e \  a r e  l t . r r  r l -
danage caD be repaired Apart  f ionr actu:r l
rnechanisms ofDNA repair .  this $i l1 requirc
some t ime \ ! i thoul cel l  p|ol i f i rat ion. ie.  ce
cycle arrcsi .  In case of extensi\ ' , .
i r repai |ablc dalnagc. Ihc prolecl i \  r
nrachiner\  can induce apoplosis or
programfted cel l  death of thc comprof l iscd
cel ls Thc p5l gene and the co espondinI]
Ternu l lmiah KPI, IKG Xl l l
prolein hl \e a central  rolc in the processes
ol cel l  . )c le anest and apoptosis through
nrechirnr\nrs rvhich arc clear ly of great
l , rpof l inrcc in protect ing the cel ls from
carcinogcrrcsis.  lhe protect ive funct ion of
p5l is lost i f  i t  i tsel f  is murared or
inacl i \ated. or i f  the cascade ofthe proteins
which p5i regulates to deal with DNA
danrar.  r .  rrnparred " Po.. ible darnage in
r h r .  r r r : r . l r '  c r y  i n c l u d c s  t l r t s  l ) a l r e r a l r o n  i n
ct.  c ' .  rr-deperdent l rndsec (Cdkr,  lhcir
!nhihir l , f i  (Cdi) .  cycl ins and the pRb family
1,1 proleins. sets of wt ich are involved in the
lrrnsilion U-om C to S phase a|ld f'rom G] to
Reasonabl\' fi]odcsl daDtage to
DNA ci ln bc rcpaircd by nrechanisrrs uhich
include nucleot ide excision repair .  base
ercisron rcpaif, nismatch repair, reversal of
simplc alkylar ion adducts by Ou
rncth! lcuanine DNA methvl t .ansferase, and
in severe cascs rvi th no or iginal  t€rnplate, by
rcconrbrral ion Although p53 controls the
D\ \  d.  In,rgr rheclpolr l .  Lhe DNA repair
proccsscs appear at least part ial ly
indepcndcnt of p5l .  Neverthel€ss, the p53,
coordinaled afrest of the cell cyclc provides
the essent ial  t inre for lh is repair  to prevent
rhe danrage l iom spreading 10 the Dext
Sencfal ion. ln addit ion. therc is er idencc
that p5l  part ic ipales at least in base excision
r < p a r r .  : r n J  ' n a 1  b e  u \ o l \ e d  i n  o t h e r  r c p a i f
pfocesses dral require proofreading.' The
rcpair  pfocesses are not infal l ib le,  and some
tlact ion of the darnage can remain ei ther
bccausc rcpair  fai ls,  is not complete or
because some erfor is reintroduced ur ing
fepair  or in subsequent repl ical ion (Fig 2).
As in thc case of or iginal  damag€,  the
'erul t ine defecr.  ma] he lolerable.
accclerate senescence or l€ad to neoplast ic
gfo$1h.
To stop the cel l  cycle after
detected DNA danlagc (Fig Ja). a set of
r I(Llrar i . rn\ , ' lerdle. lo arre.t  the Gr phds(
prevent ing the cel l  f rom enter ing the S
phase Thefe afe several  inhibi tor proteins
1ir  G arrcst.  such as p27K'pr aDd pt6rNKt".  of
which lof  e\anrple the lat ler can induce
arrest rnedialed together by pRb and the
rclalcd proleins pl l0 and p107. ' '  One ofthe
40'l
Fig L A simple model of cell cycle. including Cdk-cyclin complexes and some Cdk inhibilors that
coniribure 1o anesl ofthe cycle. For example_ as celk enier the cycle hom Co phase tnor
shown). cyclin D associares with irs caral)ric painers Cdk,4/6 from about mid-cr phase, ans
()clrn. t  ! rrrh Cdt--r  larr  In G Ofrhe opposingCdk inhibirors.  pt6\Ka' inhibirsCdk-4/6. and
p2l '"  and pl7"f  also Cdk-l  The pRb famil !  of  proteins forn complexes wirh rhe E2F
transcription factors 10 repress CL to S rralsition. while fiee E2F'will promote it. Paraltel
processes can arresl Gr.
(elluldr rc!pohses ta DNA Dnnage and Onogcnlsis h\
th! pi3 tnd p RbEIF Puthrut'!
main rout€s lbr Gr arrest after DNA damage
arc Ir i l ia led bl  p5l .  al lhoutsh al , .
no| | lunclronal pl6 ' -"  regardless ol  rhe psl
\ lanrs ma) appear i I  cancer cel ls.  C, tne\ l
a c c o u r r l \  i r r  l 5 - 4 0 o 0  , ' f  r f r e . r e J  c e l l !  a i t ( l
damage. Also olher activators including
E2Fl can induce p2I w"rr 'c 'r 'r .3 t
fhe \econd re l  o f  mechd l i tn j
after DNA damage wil l  arresl the cell  cycle
ir the Cr phase. pfevenling the cell  f ioDr
init ial ing Irro.is This L)pe ol afrc' l  I '
med ia led  a rno r )g  o the r \  b l  l 1 -3  l o .nh i ch i \
activated through p53 dependent regulation.' Ihe l4-3-3(] prolein is a cl.  cl in-dependen(
kinase iDhibitor. as is appare|t ly another
protein CADD45.' l-he !esult ing block oflhe
cell  c\cle in Cr accounts for 60-85% of the
arrested cells after DNA damage.trrrr
In case ofsufficiendy severe DNA
damage or failed repair, p53 can coordilate
the rel l  to apoplosiq fFig lb) Apoptotir
process is mediated bv a variety of signals.
and a well established proteir pfomoting
apoprosis i  Bax. which is upregulated by
p5l. Bax p.onotes release of cytochronre .
l-rom Initochoudna. leadrng Lo a cltotorir"
caspase cascade and eventually to cell death.
Bax is counteracted in this by Bcl-2, which
108
DNA danrage, and is mainly mediated by
p2lwnr( u'.  a cycl i ' r-dependent kinas€
inhibitor which is transcript ionally activated
by p53 after DNA
is repressed by p53. Other apoptosrs
promoters which are also upregulated by
p5l includc PERP, PMI-, Fas/APOl,
Kil ler/DR5. (he PIc t 'amily o[ gen€s.
PAC'608 and lCl -Bfj.  bul lheir l 'unctional
mechanisms are less well known.lurl lr
The decisions on the balance of
ccl l  c)cle arresL. DNA repair and apoptosis
are based on rhe dele(red cellular stress and
damage. and on the status of thc mobilised
defeuces (Figs 2 and i).  Dil terent cel l  rypes
caD show considerable differences in these
responses, so that for example while p53 is
genenll) irnponant in in\ol ing lhe
defences. at least in head and neck
\qrramoLrs cel l  carcinoma (HNSC(.,
apoptosis after irradiation and
chemotherapeulic tr€atment can be
independent of p53." ln general.
(arJi|n.gen<si\ can re\ult $hc 
 
lhc dcfcnuc\
fail either becaus€ they show some specific
$eakrers or simpl) by chance given
sul-f icienl t ime and accurnrrlared damage.
C. l* -112
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I)amage can also accelerate cellular aging or
\€nescence, $hich l imi is rhe number ofce,,
Tja,ta A, Conain S, RahatdjoTW, Eto K, Ikeda-MA
cycles and the prol i fer6ting l i fe span oImosr
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PilL, Fas,APOl, PlG3 ebc
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Fig 2. Main routes where failure in cellular defenc€s ro DNA damage can lead to carcinogenesis.
Note that even in case of survival with normal function, rh€ cells remain subjecr io ag'ng
(senescence) and the background rate ofaddirional damage.
Table L Some importanr .egulatory componenrs in rhe cellcycle and defence svsrems againsr DNA






cell l ines in mult icel lular eukaryotes, and
can be seen as an additional protective
mechanism against accumulating damage.
Some of the essential regulatoD
gene5/proleins of the cell  cycle and their
chromosomal mapping are )ummarised in
Table L This lrst is only a sample ot the
growing set of functional molecules
Temu Ilmiah KPPIKG XllI
inrolved in the cellular responses lo
damage. grotrrh regularion and oncogenesis.
E2F and related proteitrs io the cell
cycle progression and arrest
The E2F family of proteins are
lranscripl ion facrors required for cel l  cvcte
progression and thereby also in oncogen€sis.
Gen€/ expression Main function ChromosomalmaDoins
D5i Damase checkDoint. ariest/aDoDtosis l 7 0 l l . I
Binds MDM2 to stabilis€ D53 and arresl C 9D2l-22 '
D  l 6 ' ' Induces Gr arresr mediated by pRb, p130, pl07 9 0 2 1 - 2 2 ' '
r 2l Inhibits Cdk-cyclin, arrest ofCl 6D2l.2
lnhib ' t r  CdI-1,  arre\ r  of  G! I 2 p  l 2  -  l 2 p  1 3 . I
D l i 0 Retards Co ro G, rransuron wirh E2F4 l 6 q  l 2  2 - l  i
DRb Reiards C, ro S transition with E2F l3o 14.2
Bcl-2 Inhibits apoptosis (counteracts Ba\) l8o2l
ATM Sisnals DNA damaq€ to D53 / tvlDM2 11o22
BRCAI Promote5 apootosis.  can acr ivate o2l" ' " l 7 q 2 l
Cvcl in  D ControlofCr to S rransit ion (wrrh Cdl-4,6) l l q l l
E 2 F A P I Stimulates E2F fanscriDnon. Dromores D21 " "' l 9 0 l l
l4- l - lo Inhibils Cdk-cyclin, affest ofG, l p J 5
KiUer/DR5 8o2l
PERP 6q24
l) reading exons I0,2 and 3;2) al ternal ive r ading exons lo.2 and 3
409
Cellutat responses to DNA Ddndse and Oncogehes$ br
the p53 ah,l p R6/E2F Pathwq,s
ln thes€ processes the p53 pathway and
pRb/F2l-  palh$ay appear lo cooperdle i r)
deternilring the outcome of DNA damage
E2Fl (and probably E2F2, E2F3
ard L2Fa) binding lo pRb. as wel l  as in
paral lel  F-2F4 or E2F5 binding to pl30 (or
pl07) inh;bi ts transi t ion from Gr to S-" Also,
pl6r"*" can inact ivate th€ cycl in D-
dependent kiDases Cdk-4 and Cdk-6 that are
needed for phosphorylation of pRb to
mediate passage through Gl/S
Dephosphorylat ion of pRb (and pl l0/p107)
can release ti2F. u4rich are needed 1()
erpress the S phase regulatory genes
Furthermore. E2F protelns caD transactlvate
p l l \ ' r ' ' ' e  t r a n r c r i p r i o n .  l e a d i n g  I o  C l
Loss of PRb f'unction leads to loss
of Or arr€st and can result ilr apoptosis atler
DNA damage. Simultaneolsl)  rncreasrDg
amount of f ree E2l:  Promotes the
prosressiol  of  the cel l  cycle. ln this way
loss of pRb is equivalent ln outcome 1{)
overcxpress;on of E2F- lnversel, ' ,
overexpression of pRb can also block p53_
depe| ldel l l  apoplosic. '  l r rdependet l l  oI  i ts
apoptotic functiorl- Bcl-2 can incr€ase
p l - \ r  l r n d  p l i U  l e \ e l -  t o  r n a i r r t a i n
conrplexes of pl30 and E2F4. These
conplcxes retafd the transi t ion from Co to
C .  possibly by delaying E2Fl expression '
E2Fl is a cel l  cycle pronoter.  bul
also a potenl ial  oncogenic signal inducing
pl4oRF, which can bind MDM2 and thereby
rlab l i re p5l and prornote dpoplo( i \  in
prcs€nce of conrbined increasirrg levels ot
pl1^* '  and u2Fl.  ' '  fhe E2Fl protern
contains a basic hel ix loop-hel ix (bHLH)
h\drophobic / ipper - t fuclure required lor
DNA bindirrg aDd dimerizat ion in the central
section, and a transactivafion domain in the
C{erminal part  of the molecule- '"
L2F acrrviry is generaled br
formal;on ofheterodimers bel$een f2F |  (or
one of rhe related proleins F2F2 lo t2F) )
and DPI (or one ofthe related proteins DP2
or DP3). The resulting heterodimers have
greater Dn-A bindiDg activiry than any ofth€
homodimers, which in this \'aY act
synergistically in E2F site-dependent
rranscr ipt ional actrvalrorr.  The E2F \r le-
dependent ranscription, in cooperatioD wilh
E2Fl,  is st imulat€d by E2FBPl,  a protein
with a HLH moti l  but lack;Dg thc basic and
zipper structures found around HLll in
L.2l-  I  '6 Ihe corrr .ponJrrg gene coditrg for
E:FBP I , also called ,,R]r1. is a homolog ot
the murine 6r i8r l  and Drosoplr i la J. . . rd
r/r?ger eenes. $hrch ho$e!er hare di l lnrett t
f 'unct ions.r t
E2l-BPl has been recerrt l )  beerl
.ho$r io be direct l )  reeulaled by p5l.
Ectopic expression of E2FBPI activates
t 2 l $ " '  P '  i n  c o o p e i a t i o n  $ ; t h  p 5 j .
inducing growrh arrest which fai ls in cel ls
def i  c ienl  iD funct ional p5l . ' "
I  hrs proce\s lealure5 lhercfore !el
another link between the PRb/E2F
depeDdent growth regulat ion a' ]d the pi l
d e p e D d e r t  p a l h \ a ) ' .  I h e s e  p a r h s a l s  c a r r  b e
interfered in oncogenesis by intercepling
any ofthe principal regulating factors on the
p53 to p2lw"nc'pr axis,  or al ternat ively on
t h e  p l o r \ K a "  t o  p R b  a x i ' .  i n c l u d i r r g  l h e  c )  c l i n
dependent kinases, aDd various inhibitors
and acr i \ators within lhe'e s)ctelns. Ihc
interdepencencics of thcse inlerwoveD
systems arc chamcterised by silnplified
models shown iD Fig l .
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Mo 2 FarM ---------) BRcal\ r '  +
F.s/APOl <- D53 _--|' GADO45l^",""lZJV",i*^,,
| | ' ' : .  I  Bcr2--rBax+  + + +  +  +
a) ol
Fig L Simple models of a) the celh:lar €ycle arrest regulation, showing links betwe€n p53 and
pRb/E2F pathways; and b) apoptosis mainly including psl-dependent pathwavs An arrow
signifies activatiorl/promotion f process direction, a lin€ with a terminal bar inhibition. Note
that several of the indical€d regulatory molecules appear in reality as a family of proteins
rrrh mostly parallel tunctions. e.g. rhe INK lamily of kinase inhibitors includes pl6rNK".
p t5rNNb. ptSrNKt and plqrNud
Discussion
h is notable that the same $pe and
extent of DNA damage can lead to DNA
r€pair in some cell types while inducing
apoptosi: in others. ' ln principle this could
reflect cell specific differences either tn
sensrt iviry to apoplosis or in lhe relal ive
inrensir ies of. the repair and apoptotic
mechanisms (or both). bul the aclual
mechanisms are large,y obscure. Cell lype
related differences are known tbr example
of the p53 fatnily members p73 and p63,
which tend to be restricted to certain tissues.
However, the only member of lhe famil)
with undisputed role in the cellular defences
is p53, which is ubiquitously expressed rn
a l l ce l l s . l '
lf ps3-mediated repair and cell
cycle arrest functions were very essential for
mainlaining the integity ofthe Benome, p5l
and its functions could be expected to be
widely conserved in evolution.5 Although
Temu l lniah KPPIKG XIII
p53 appears in mammals with typical
consened transcriptronally actir e region'
no p53 even in primitive form has been
found in prokaryotes or in most groups of
simple eukaryotes. A p53 homolog does
occw in Drosophila, but does not have a
role in c€ll cycle arrest, only in apoptosis
lrhich may be the original funcl ion of p5l' I  here are proleins (such as E2Fl and
BRCA | ) $ hich can transacl i \ ,ale p2lo"" '  '"
in p5l- independenl fashron". and other
fearures ot the cellular defences hich are
bener evolutionari ly conserved lhan p53
Several essential molecules in the cellular
defences appear to be related to systems of
growth, development and differcntiation
This is not only true from compaison to
non-human homologs but also wilhin human
cells. For example the regulatory proteins
p?3 and po3. which probabl) are relat€d to
the ancestor f p5l. are acl ive mainly durinE,
embryonal development rather than in tumor
suppression.' t tu
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Ce ulat rcsponses to DNA Danaqe and Oncogenesis bv
the pt3 and p Rb/E2F Pathwoys
Io (vol \e.  lhe p5l-dePendent
defences of complex eukaryotic organrsms
rherefore musl hdre had selecl i !e advanlage
which is \aeaker or not presenl in simple
orgaDisms. It is conceivable that the
compler i t l  i rsel t  jo the cel lular regulal ion
sy\rems could pror ide this ad'"antape.
because increasing complexi ty provides arr
increasing number of attack points for
oncogehrc darnage. Anolher feason could be
rclared !o longe\ i l )  ol  organirms. Wir l r
l c r g e r  l i l c  o t  a r r  r r r d i r i d u a l .  w h i c h  l e n d s  t o
be ro'r !hl)  related to lhe bod) si /<.
nretabolic rale and other features of
physiology. lhere is an iDcreasing charce of
accumulat ing sigDif icant damage during the
reproJl lch!e penod. and t  her<f, , r  e
presumably some selective pressure tbr
irrproved defences. Funher comparisons of
rhe p) I  homolog luDcl ions $ i lh iD
renehrates and inrenebrates i '  l ikel l  t . t
c lar i fy th€ issue.
The selccl i !c advanlage aspecl
exlends lo pathogens inducing DNA
ddrnage lor e: .ample. i t  i '  ar advantaBe lo
vifuses tc inactivate p5l or its function fof
repl icar ioi t  heir  own genorne. E.g. l lBV
\! l l |ch ercudc\ a prolet |r  (  HBXAg) birrdi l 'g
to p5l and pievent i t lg i ls t ransact ivat ion. rs
thoughl lo be i rrrolved rn I l te palhoqenesi.
of 90% of h€patocarcirromas.' Similarly, the
HCV core prolei | |  can repress basal ano
induced p2l w'rr /c 'er t ranscr ipt ion and
therefore iDtercept the p53-regulated cell
c lc le arrest.e Pathogens typical ly have
.ereral  paral lel  nre"harr iqm. lo disartn thc
host def'ences, and can also challenge other
cnocal ooints of the reeulalon s\stem l ike
the pRb/E2F pathway.
Also carcinogenesis requires
selective advantage for proliferation of
neoplast ic el ls.  These cel ls must overconre
the defences and l ike with the palhogens.
L h t \  c a l l  b e  d o n e  i n  a  \ a n e l \  o f  \ a l s .  a \  i .
ref leLted in lhe di l terence5 bet\e(n
drt lefenl types of carrcer.  and lumors.
Hotre\er,  Ihere are a fen common leatu'eq
lor nearl)  al l  cancers. Lxcluding rare special
cases. like retinoblastoma (embryonal eye
ca' lcer due ro los. of  pRb,).  epidemiological
studies suggest thal on average about stx
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(rvith extremes of3 to 12) oncogenic events
are required to develop cancer.'' The classic
anal)sis lor thi5 purpose has assumed that
the rate determining event oI carcinogenesis
is the neoplastic transformation of a single
ini t iat ing cel l .  I  he as'umpl ion is nol
consijtent wilI observed |r? v/vo mutation
ralel  or cdncef incidence in human. $i lh
hereditary oncogeDic defects.:r The
discrepancy is explained if the rate
determ|lr i rg e!ent r5 assumed lo invol\e
Inany r up lo thou\ands) of cel l . .  and indeed
,nlercel lular s ignal l ing via FCFR arrd orher
factors between cells, aDd ccll group events
such as angiogenesis are now se,en essential
for the growth ofmost tumors.'' '
l h u r  l h c r e  a r e  i r r r p u r l a n l
di l lerence5 belscen ini l ia l  oncogcnic e\etr l5
related to the defences ofa singular cell, and
acrual de\elopnrenl of  lumors lhe laner
Inus! be scen as a dynamic process of
simultaneous prol i ferat ion, groM
coordinatiorr and apoptosis of initiated cell
groups. For exarnple, while apoptosis js an
essential defensive mechanism after s€vere
DNA darndgc. in.reasirrg rate ol  apoplo. is
in tumors is general ly a sign of advanced
stage arrd poor progrrosis rather than the
opposire.rr Although iidu.ed apoptosis by
irradiatioD and chemotherapeutic ag€nts rs
appl ied in caDcer therapy. the resul l ing
a d d i l i o n a l  s u r \ i \ a l  t i m e  i s  r r o l  a l $ a l s  v e r l
long.: '  Ih is paf l l )  ref lecls lhe disadvanlaFe
lrorn cornpronrised genomii  defente' .  and
partly the s€leclive advantage fbr resistant
cel t .  r l ,Ar cdn adapt lo lhe l rcdtmenl and
prolil€rate. ln principl€ it were ar advantage
to loni l )  rhe defence'  i r*ead ol  onl ,
rnr l 'gal i r)g lhc consequences. and nelt
cancer trealments to this eflect are being
tested.ra Frorn the application poirlt ofview,
this is obviously one of the dr iv i ig forces
for the crrrent research inlo lhe cellular
dcfences agaiDsl DNA damag€.
The mammalian genome has high
reacrrr i ty and rnay undergo over I00
modi l lcal ion'  a day. This r)  " igni f icant
af lack in sprte of the larg€ s ize ol  lhc
genome- aboul I  bi l l ion base pairs.  ofwhich
perhaps 4oo Is coding sin(e lhe
rnodrf icatrons a| |d lheir  consequences are
T€mu llniab KPPIKG xlll
)telkdti El 5L\.lr lS ljutta 1. ( ornatn S Rahu ljo Ttl. Ero K. lke.la-MA
nol fandonr.  Classic examples ol_
carcinogenic signafures iD p5l are hot spol
codon mutat ions. l ike Uv-related C + l  and
CCJTT conversions, af laloxin B-induced
C;)'t changes. tobacco related GJl and
GrC mutat ions. aDd AJT and TrA
altemtioDs associated with vinyl  chlor ide."
In geDeral.  al terai ion or loss ofexpression rn
tumors concentrate on regulalory factors
l i k c  p 5 3 .  p R b ,  p 1 6 N K 1 " .  p l l s d r c r ' ,  p 2 7 k ' l
aDd other tumor suppressor faclors iD the
n e t w o r k s  o f  t h e  c e l l u l a r  d e l _ e n c e s r r 6 q r r i r
Nevenheless. cvcn wi lh such del 'ects and
subsequeDtly increased cancer r isk.  maD\
individuals predisposed to defec{s in drese
r e : L U l a l o r \  l d ( t o r .  r r l l  n o r  . u l r c r
'l'able 2. Lisi ofabbrevialions.
(arci | lo lerrc- is \pan lrom rhe rrme aDd
exposure lo damaging agents required to
accumularc the necessan lumber of
oDcogenjc events. this probabl) also reflects
the redundaDcies of the networks of the
delence s]stems. Much needs to be clarified
i I  rhc i | | i rctronal mechanism\ of lhes!
relsork\ Jnd their  molecular cunpo ent\ .
ol '$hich nrarr)  remain ]ct  to be found and
characterised.
Meaning
A R F 4lref l  f l i \  L  reaJrng f r inu
A I M AtJ\ id  l (  Jn! i<(rds i r  nrurared ( -ene)
ATR A lM Radi ' re lated (Sene)
Bax Bcl 2 antagonist-X
Bcf2 lymphoma/leukemia - 2 (gene)
cdk C) c l i r i -drptnJent  l i r ra\e
Cdi (or Cki) C)c l in-dcp.ndent  k inase inhib i tor
E G F R l pidenri l  t ro$rh fa(ror eceptor
E ] F B P I l l f  b indi t rg prote i r  I
CAI]D45 Ci N'h d, ( \ r  dnJ DNA danra:e 15 (gene)
HBV l  HCV Hcparir is U C virus
HPV Hunan papi l lonra virus
I N K l h ib i to f  o l  cyc l in  dependent  k inase
JNK c - i u n  N - t e l n i n a l k  n d \ e
MDM Murine doublr  m nures (ge| le]
p Prorein (or chron)o\omc sht 'a arm)
PERP p5l apoptosis effector elated to PMP-22
PCN,A Prol i ferat ing cel l  nuclear  ant igen
PIG p5l- induced gene
pRb Rct inoblas lonra prote in
ChroDrosoDre long arm
UV L l l rd \  iu lcr
Temu l ln iah KPPIKG Xl11 4 1 3
Cellultt lespanse! 1o DliA Dandge andOn.rgenesi! bl
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